Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
84%
Rituximab
74%
Diseases
70%
Radiation Therapy
59%
Progression Free Survival
54%
Non-Hodgkin Lymphoma
51%
Overall Survival
50%
Follicular Lymphoma
45%
Mantle Cell Lymphoma
43%
Large-Cell Lymphoma
37%
B-Cell Lymphoma
32%
Hodgkin's Lymphoma
27%
Malignant Neoplasm
26%
Survival Rate
26%
Doxorubicin
25%
Cyclophosphamide
25%
B Cell
25%
Lenalidomide
23%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Ibrutinib
20%
MALT Lymphoma
20%
Chimeric Antigen Receptor T-Cell Immunotherapy
18%
Vincristine
17%
Classical Hodgkin Lymphoma
16%
Neoplasm
16%
Positron Emission Tomography-Computed Tomography
15%
positron emission tomographic scan
15%
Central Nervous System
14%
Adverse Event
13%
Phase II Trials
13%
Lymphocytic Lymphoma
13%
Arm
12%
International Prognostic Index
12%
Methotrexate
12%
Lymphoma Cell
12%
Clinical Trial
12%
Allogeneic Stem Cell Transplantation
11%
Prednisone
11%
Burkitt's Lymphoma
11%
Axicabtagene Ciloleucel
11%
T Cell
11%
Oncology
11%
Hazard Ratio
11%
Disease Exacerbation
10%
Autologous Stem Cell Transplantation
10%
Cytarabine
10%
B-Cell Chronic Lymphocytic Leukemia
10%
Peripheral T-Cell Lymphoma
9%
Systemic Therapy
9%
Obinutuzumab
9%
Keyphrases
Rituximab
80%
Diffuse Large B-cell Lymphoma (DLBCL)
69%
Mantle Cell Lymphoma
56%
Relapsed or Refractory
52%
Follicular Lymphoma
48%
Progression-free Survival
43%
Complete Response
38%
Cyclophosphamide
31%
Phase II Study
31%
Overall Survival
30%
Radiation Therapy
28%
Chemotherapy
28%
Lymphoma
27%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
26%
Large B-cell Lymphoma
26%
B-cell Lymphoma
24%
Doxorubicin
24%
Non-Hodgkin Lymphoma
23%
Phase II Trial
23%
Lymphoma Patients
22%
R-CHOP
20%
Chimeric Antigen Receptor T-cell Therapy
19%
Overall Response Rate
19%
Lenalidomide
19%
Newly Diagnosed
18%
Cytarabine
17%
Hyper-CVAD
16%
Advanced Stage
16%
NCCN Guidelines
16%
Ibrutinib
15%
Partial Response
15%
B-cell non-Hodgkin Lymphoma (B-NHL)
15%
Bortezomib
14%
High Risk
14%
MD Anderson Cancer Center
14%
Previously Untreated
13%
Confidence Interval
13%
Radiotherapy
13%
Prednisone
13%
Fludarabine
13%
Failure-free Survival
12%
Methotrexate
12%
T Cells
12%
Chimeric Antigen Receptor T Cells (CAR-T)
12%
Peripheral T-cell Lymphoma
12%
Neutropenia
12%
Disease Progression
11%
Obinutuzumab
11%
International Prognostic Index
11%
Positron Emission Tomography-computed Tomography (PET-CT)
11%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Diffuse Large B Cell Lymphoma
54%
Nonhodgkin Lymphoma
50%
Mantle Cell Lymphoma
48%
Diseases
43%
Chemotherapy
42%
Progression Free Survival
40%
Cyclophosphamide
36%
Overall Survival
34%
Follicular Lymphoma
33%
Doxorubicin
29%
Malignant Neoplasm
27%
Vincristine
26%
Lenalidomide
23%
Remission
23%
Survival Rate
22%
Cytarabine
20%
Methotrexate
20%
Large Cell Lymphoma
19%
Chimeric Antigen Receptor
19%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Dexamethasone
17%
Neoplasm
16%
Phase II Trials
15%
Prednisone
15%
B Cell Lymphoma
15%
Ibrutinib
14%
Failure Free Survival
14%
Hodgkin Disease
14%
Adverse Event
13%
Bortezomib
13%
Clinical Trial
12%
Neutropenia
11%
Fludarabine
11%
Obinutuzumab
11%
Thrombocytopenia
10%
Classical Hodgkin Lymphoma
9%
Angiofollicular Lymph Node Hyperplasia
9%
Disease Exacerbation
8%
Etoposide
8%
Event Free Survival
7%
Monoclonal Antibody
7%
Axicabtagene Ciloleucel
7%
Siltuximab
6%
Denileukin Diftitox
6%
Danvatirsen
6%
Pentostatin
6%
Inotuzumab Ozogamicin
6%
Interleukin 6
6%
Myelodysplastic Syndrome
6%